The immunodiagnostics group, Oncimmune Holdings’ shares boosted 7% to 135p after the company announced signing two new ImmunoINSIGHTS commercial contracts.
The first agreement is to develop first-in-class cell immunotherapy for cancer patients using commercially available natural killer cells and CARNK cell products with a US-based clinical-stage bio-pharmacy company.
Based on this agreement, Oncimmune will use its unique high-throughput biomarker detection platform, SeroTag, to identify autoantibodies that can predict positive resistance whilst potentially addressing patient clinical response and engineered cell therapy in the haematology and oncology indications of solid tumours.
This new deal illustrates the company’s ImmunoINSIGHTS technology platform’s enormous potential in the engineered cellular treatment market.
The second agreement was made with a clinical-stage biopharmaceutical company based in the United States that is developing a proprietary technology that utilises the immune system’s strength to battle cancer by leveraging their proprietary technology to ‘discover, develop, and commercialise transformative oncology treatments’.
The autoantibodies in patients treated with a virus-like substance that boosts anti-tumour T cells will be explored in this effort.
The project’s goal is to demonstrate how this medication affects the immune system by profiling patients over time.
“We are pleased to announce a further two contracts with our ImmunoINSIGHTS platform which demonstrates the progress that our Commercial team are making from our new US office in Boston,” stated Dr Adam M Hill, CEO, Oncimmune.
“We are particularly excited by the signing of our first contract within the allogenic and CAR-NK market segment which we believe could open up a new opportunity for our services in the engineered cellular therapy space.”
“Unlocking the utility of the ImmunoINSIGHTS platform in these cutting-edge therapies promises to substantially improve clinical outcomes for cancer patients.”